- A major project to manage Samsung Bioepis’ global supply chain using o9’s IBP platform is underway.
- Scenario planning features will enable timely responses to market and operational challenges.
- This can be swiftly applied to all phases of short-, medium-, and long-term planning.
January 18th, 2021 – Seoul, Korea – o9 Solutions, a premier AI-powered IBP platform provider, announced that it would supply its next-generation platform to Samsung Bioepis Co., Ltd., bolstering the management of its biopharmaceutical product manufacturing and supply chain. o9 Solutions’ platform will also help Samsung Bioepis optimize its focus on development, clinical trial management, and regulatory registration.
o9 Solutions’ unique platform, or ‘digital brain’, supports all planning phases, including long-term strategic planning to medium- and short-term execution. The platform will be integrated into the client’s existing enterprise resource planning (ERP), seamlessly providing efficiencies in supply chain management, financial management, and collaboration.
The integration of o9 Solutions’ digital brain into Samsung Bioepis will allow the company to leverage AI and analytics to streamline commercial planning, revenue planning, and gap closure activities. This conversion of data into knowledge will enable a better understanding of how best to drive initiatives from new products to marketing and pricing for incremental impact and an optimal mix of investment.
Chakri Gottemukkala, CEO of o9 Solutions, said, “Our SCM platform contract with Samsung Bioepis is o9 Solutions’ first project with a biopharmaceutical company, and we are very honored. We will be actively supporting Samsung Bioepis in its efforts to enhance productivity and reduce costs by providing our solutions to manage and plan pharmaceutical manufacturing and distribution.”
“We will be actively supporting Samsung Bioepis in its efforts to enhance productivity and reduce costs by providing our solutions to manage and plan pharmaceutical manufacturing and distribution.” said Chakri Gottemukkala, CEO of o9 Solutions
About Samsung Bioepis
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world’s leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com and follow us on social media– Twitter, LinkedIn.
